Evidence map›Paper›PMID 31273050›Full record

ArticleClinical science (London, England : 1979)2019

Impact of ET-1 and sex in glomerular hyperfiltration in humanized sickle cell mice.

Malgorzata Kasztan, David M Pollock

Abstract readComparative Study
In one paragraph

Article in Clinical science (London, England : 1979), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Glomerular hyperfiltration: part 2-clinical significance in children.Pediatric nephrology (Berlin, Germany) · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Malgorzata KasztanSection of Cardio-Renal Physiology and Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, U.S.A.
David M PollockSection of Cardio-Renal Physiology and Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, U.S.A. davidpollock@uabmc.edu.ORCID 0000-0002-0233-2362
University of Alabama at Birmingham · US

Funding

The Role of Endothelin-1 in Sickle Cell DiseaseU01HL117684 · NHLBI · AUGUSTA UNIVERSITY · PI KUTLAR, ABDULLAH, MEILER, STEFFEN · 2013 to 2017
$8.1M
The Role of Endothelin-1 in Tubular Injury in Sickle Cell DiseaseR00HL144817 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KASZTAN, MALGORZATA · 2021 to 2023
$747k
The role of endothelin-1 in tubular injury in sickle cell diseaseK99HL144817 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KASZTAN, MALGORZATA · 2019 to 2020
$306k
NHLBI NIH HHS K99 HL144817NHLBI NIH HHS R00 HL144817NHLBI NIH HHS U01 HL117684
6 · The paper itself

Abstract

Hyperfiltration, highly prevalent early in sickle cell disease (SCD), is in part driven by an increase in ultrafiltration coefficient (K

Indexed as

Glomerular Filtration RateAnemia, Sickle CellAnimalsDisease Models, AnimalEndothelin-1Endothelin A Receptor AntagonistsFemaleHemoglobin AHemoglobinsHumansKidney DiseasesKidney GlomerulusMaleMice, TransgenicMutationPhenylpropionatesambrisentanEndothelin-1Endothelin A Receptor AntagonistsHemoglobin Ahemoglobin BHemoglobinsPhenylpropionatesPyridazinesendothelin-1hyperfiltrationsickle cell diseaseultrafiltration coefficient

Identifiers

PMID31273050
PMCPMC13673563
OpenAlexW2955022130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.